GlassScriptPhysician profile
Charles Spielman
NPI 1851549356
$9,146.05
in general payments reported to CMS, 2019-2025
44 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,009 · 2021: $1,686 · 2022: $1,100 · 2023: $1,766 · 2024: $952 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,075.78 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,039.02 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $701.74 | 2019-2024 | Farxiga, Breztri, Wainua |
| Impulse Dynamics (USA) INC. | $582.78 | 2019-2023 | Optimizer |
| Teva Pharmaceuticals USA, INC. | $564.73 | 2019-2024 | Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.04 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $377.10 | 2019-2022 | |
| Amgen INC. | $296.86 | 2019-2023 | Repatha |
| Arbor Pharmaceuticals, INC. | $278.70 | 2019-2021 | |
| Boston Scientific Corporation | $275.39 | 2019-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $254.46 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Acadia Pharmaceuticals INC | $244.82 | 2023 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $215.28 | 2019-2025 | |
| Cardiovascular Systems INC. | $204.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.41 | 2021-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.82 | 2019-2023 | Lifevest |
| Inari Medical, INC. | $131.82 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $130.03 | 2019-2021 | |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Ucb, INC. | $124.85 | 2024 | Nayzilam |
| Sumitomo Pharma America, INC. | $123.61 | 2023 | Gemtesa |
| Neurocrine Biosciences, INC. | $123.35 | 2024 | Ingrezza |
| Celgene Corporation | $122.40 | 2021 | |
| Sk Life Science, INC. | $118.02 | 2023 | Xcopri |
| Sunovion Pharmaceuticals INC. | $116.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $114.95 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $111.04 | 2019 | |
| Nestle Healthcare Nutrition INC. | $109.82 | 2021 | |
| Koya Medical, INC. | $108.49 | 2025 | Dayspring, Koya Medical |
| Lilly USA, LLC | $108.20 | 2019 | |
| Lundbeck LLC | $67.97 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $67.49 | 2022-2025 | Edarbi, Edarbi |
| E.R. Squibb & Sons, L.L.C. | $67.11 | 2021-2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $53.04 | 2023 | Inpefa |
| Agepha Pharma Fz LLC | $35.62 | 2025 | Lodoco |
| Watermark Medical, INC. | $32.29 | 2024-2025 | |
| Cvrx, INC. | $31.26 | 2024-2025 | Barostim Neo System |
| Akcea Therapeutics, INC. | $30.67 | 2019-2020 | |
| Pfizer INC. | $26.24 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $22.40 | 2019 | |
| Abbott Laboratories | $17.96 | 2020 | |
| Angiodynamics, INC. | $13.68 | 2019 | |
| Medtronic Minimed, INC. | $12.10 | 2020 | |
| Vivaquant INC, Dba Rhythm Express | $10.57 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Spielman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.